Progress in T cell receptor-gene engineered T cell immunotherapy for solid tumors / 肿瘤
Tumor
; (12): 256-263, 2018.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-848413
Biblioteca responsável:
WPRO
ABSTRACT
T cell receptor-gene engineered T cells (TCR-T) therapy is a kind of tumor adoptive immunotherapy based on the modified T cells, which can generate a strong anti-tumor immune effect in vivo by virtue of its high affinity recognition of tumor-specific antigens. Many I/II-phase clinical trials have shown the safety and effectiveness of TCR-T in treatment of solid tumors, especially melanoma and synovial cell sarcoma. However, the clinical immunotherapy of TCR-T cells has also brought some challenges, such as off-target toxicity, cytokine release syndrome and neurotoxicity. It is predicted that the efficacy and safety of TCR-T immunotherapy can be improved by screening for high-affinity TCRs, reducing adverse reactions of TCR-T cell immunotherapy and other ways. And with the deepening of research, TCR-T immunotherapy will bring new hope to the patients with tumor.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Estudo prognóstico
Idioma:
Chinês
Revista:
Tumor
Ano de publicação:
2018
Tipo de documento:
Artigo